IASO Approved to Start China Trials of Dual CAR-T for B-Cell Malignancies

ASO Bio, a Nanjing biotech, was approved to start clinical trials of its autologous CD19/CD22 CAR-T therapy for two indications. IASO said CT120’s dual-target design addresses tumor escape, a problem caused by target antigen loss that affects existing CAR-T therapies. The company expects CT120 will reduce relapse and improve survival. In-house developed CT120 will be tested to treat relapsed/refractory B-cell non-Hodgkin's lymphoma and relapsed/refractory B-cell acute lymphoblastic leukemia. In general, IASO targets B-cell malignancies. More details.... Share this with colleagues: // //